| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
1 company
Heidi Hunter is a corporate insider. Heidi Hunter's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $21K at current prices.
Net of sales, the IOBT filings show accumulation of 15,000 shares.
Heidi Hunter has 11 Form 4 filings on record from November 2021 to June 2026, across 2 companies: Director at Sutro Biopharma (STRO), 2021–2026; IO Biotech (IOBT), 2023–2025.
The 12 reported transactions were 11 option or other derivative awards and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $21K and no sales.
The only open-market purchase was 15,000 shares of IOBT at an average $1.39 on May 30, 2025, about $21K. Twelve months later IOBT was down 100%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 30, 2025 | IOBT Io Biotech, Inc. | - | Buy | 15,000 | $1.39 | $20,884.50 | New | +11.3% | -99.8% |